Literature DB >> 6607783

Disturbance of 6-mercaptopurine metabolism by cotrimoxazole in childhood lymphoblastic leukaemia.

C A Rees, L Lennard, J S Lilleyman, J L Maddocks.   

Abstract

The effect of cotrimoxazole on the utilization of 6-mercaptopurine (6MP) was studied in a group of children receiving remission maintenance treatment for lymphoblastic leukaemia (ALL). This was done by measuring the level of an active metabolite of 6MP, 6-thioguanine nucleotide (6TGN), and comparing it both with the drug dose and with subsequent neutropenia in the presence or absence of concurrent cotrimoxazole. In children who were not taken cotrimoxazole, the concentration of 6TGN showed a significant positive correlation with the dose and a significant negative correlation with the absolute neutrophil count 2 weeks later. In those who were taking the antibiotic both these relationships were lost. This suggests that cotrimoxazole can interfere with both the absorption and the cytotoxicity of 6MP and may, in turn, alter its antileukaemic effect.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6607783     DOI: 10.1007/bf00254595

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  Letter: Co-trimoxazole and the blood.

Authors:  S el-Tamtamy
Journal:  Lancet       Date:  1974-05-11       Impact factor: 79.321

2.  Binding of drugs to human serum albumin XVII: Irreversible binding of mercaptopurine to human serum proteins.

Authors:  I Sjöholm; B Stjerna
Journal:  J Pharm Sci       Date:  1981-11       Impact factor: 3.534

3.  Enteropathy complicating maintenance therapy in acute lymphoblastic leukaemia.

Authors:  I J Lewis; D Mainwaring; J Martin
Journal:  Arch Dis Child       Date:  1982-09       Impact factor: 3.791

4.  Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia.

Authors:  L Lennard; C A Rees; J S Lilleyman; J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

5.  Toxicity of trimethoprim-sulphamethoxazole in patients with megaloblastic haemopoiesis.

Authors:  I Chanarin; J M England
Journal:  Br Med J       Date:  1972-03-11

6.  Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red blood cells.

Authors:  L Lennard; J L Maddocks
Journal:  J Pharm Pharmacol       Date:  1983-01       Impact factor: 3.765

7.  Successful chemoprophylaxis for Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; S Kuhn; S Chaudhary; S Feldman; M Verzosa; R J Aur; C Pratt; S L George
Journal:  N Engl J Med       Date:  1977-12-29       Impact factor: 91.245

8.  Suppression of thymidine uptake of human lymphocytes by co-trimoxazole.

Authors:  P M Gaylarde; I Sarkany
Journal:  Br Med J       Date:  1972-07-15

9.  6-Mercaptopurine: apparent lack of relation between prescribed dose and biological effect in children with leukaemia.

Authors:  S Herber; L Lennard; J S Lilleyman; J Maddocks
Journal:  Br J Cancer       Date:  1982-07       Impact factor: 7.640

  9 in total
  8 in total

1.  Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia.

Authors:  P Lafolie; O Björk; S Hayder; L Ahström; C Peterson
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

2.  Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia.

Authors:  P Lafolie; S Hayder; O Björk; C Peterson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Antineoplastic agents. Drug interactions of clinical significance.

Authors:  E van Meerten; J Verweij; J H Schellens
Journal:  Drug Saf       Date:  1995-03       Impact factor: 5.606

4.  The effect of cotrimoxazole on the absorption of orally administered 6-mercaptopurine in the rat.

Authors:  N K Burton; G W Aherne
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 5.  Pharmacokinetic drug interactions with anticancer drugs.

Authors:  P M Loadman; M C Bibby
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

6.  The effect of folate supplements on 6-mercaptopurine remission maintenance therapy in childhood leukaemia.

Authors:  L Lennard; J S Lilleyman; J L Maddocks
Journal:  Br J Cancer       Date:  1986-01       Impact factor: 7.640

7.  Childhood lymphoblastic leukaemia: sex difference in 6-mercaptopurine utilization.

Authors:  J S Lilleyman; L Lennard; C A Rees; G Morgan; J L Maddocks
Journal:  Br J Cancer       Date:  1984-06       Impact factor: 7.640

Review 8.  Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction.

Authors:  Kjeld Schmiegelow; Stine N Nielsen; Thomas L Frandsen; Jacob Nersting
Journal:  J Pediatr Hematol Oncol       Date:  2014-10       Impact factor: 1.289

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.